Trials Sponsors Conditions Drugs Pricing

Conditions

HIV Infections

Keywords

HIV childrenHAARTARVSecond line HAARTViral LoadCombination drugTreatment ExperiencedTreatment Naive

Outcome Measures

Primary Outcomes (1)

1. To collect clinical and immunologic data of children treated with HAART 2. To collect clinical outcome data on children with HIV infection 3. To provide the best possible care to children with HIV infection
every 3 months

Study Arms (1)

Long-term pediatric cohort

Long-term follow-up cohort since 2003

Drug: Zidovudine, Stavudine, Didanosine, LamivudineDrug: Nevirapine, EfavirenzDrug: LPV/r, Saquinavir, Indinavir, Ritonavir, Nelfinavir

Interventions

Zidovudine, Stavudine, Didanosine, LamivudineDrug

Refer to the Thai guideline for HIV management 2007

Long-term pediatric cohort

Nevirapine, EfavirenzDrug

Refer to the Thai guideline for HIV management 2007

Long-term pediatric cohort

Registry intervention entries

These entries preserve how the registry describes the intervention. Their treatment roles are shown separately from molecular identities.

Grouped treatment entry
Zidovudine, Stavudine, Didanosine, Lamivudine
The registry names several treatments. This does not confirm that participants received them together or that they form a single product.
View registry record
Grouped treatment entry
Nevirapine, Efavirenz
The registry names several treatments. This does not confirm that participants received them together or that they form a single product.
View registry record
Grouped treatment entry
LPV/r, Saquinavir, Indinavir, Ritonavir, Nelfinavir
The registry names several treatments. This does not confirm that participants received them together or that they form a single product.
View registry record

Eligibility Criteria

Age1 Day - 20 Years

Sexall

Healthy VolunteersNo

Age GroupsChild (0-17), Adult (18-64)

Sampling MethodNon-Probability Sample

Study Population

HIV-infected infants, children and adolescents (range age 1 day - 20 years old) who have participated in HIV-NAT trials

You may qualify if:

Children who are part of the ATC program at Chulalongkorn hospital and at HIV-NAT, The Thai Red Cross AIDS research center

Sponsors & Collaborators

Khon Kaen University
Othercollaborator
The HIV Netherlands Australia Thailand Research Collaboration
Otherlead

Study Sites (3)

HIV-NAT

Bangkok, 10330, Thailand

Pediatric infectious diseases section, Chulalongkorn University

Bangkok, 10330, Thailand

Khon Kaen University

Khon Kaen, 40002, Thailand

Related Publications (3)

Bunupuradah T., Puthanakit T., Boonrak P., Butterworth O., Mengthaisong T., Intasan J., Ubolyam S., Kosalaraksa P., Engchanil C., Pancharoen C., Lumbiganond P., Phanuphak P., Ananworanich J., HIV-NAT Pediatric Study Team. Efficacy and safety of non nucleoside reverse transcriptase inhibitor (NNRTI) based highly active antiretroviral therapy (HAART) in Thai children with HIV, poster No. TUPEB128. Poster presented at the 4th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention, Sydney, Australia, July 22-25, 2007
RESULT
Bunupuradah T, Puthanakit T, Kosalaraksa P, Kerr S, Boonrak P, Prasitsuebsai W, Lumbiganon P, Mengthaisong T, Phasomsap C, Pancharoen C, Ruxrungtham K, Ananworanich J. Immunologic and virologic failure after first-line NNRTI-based antiretroviral therapy in Thai HIV-infected children. AIDS Res Ther. 2011 Oct 26;8:40. doi: 10.1186/1742-6405-8-40.
PMID: 22026962RESULT
Sirikum C, Sophonphan J, Chuanjaroen T, Lakonphon S, Srimuan A, Chusut P, Do TC, Prasitsuebsai W, Puthanakit T, Ananworanich J, Bunupuradah T; HIV-NAT 015 study team. HIV disclosure and its effect on treatment outcomes in perinatal HIV-infected Thai children. AIDS Care. 2014;26(9):1144-9. doi: 10.1080/09540121.2014.894614. Epub 2014 Mar 13.

Biospecimen

Retention: SAMPLES WITH DNA

PBMC

MeSH Terms

Conditions

HIV Infections

Interventions

ZidovudineStavudineDidanosineLamivudineNevirapineefavirenzSaquinavirIndinavirRitonavirNelfinavir

Condition Hierarchy (Ancestors)

Blood-Borne InfectionsCommunicable DiseasesInfectionsSexually Transmitted Diseases, Viral

Study Officials

Kiat Ruxrungtham, MD, MSc
HIV-NAT, The Thai Red Cross AIDS Research Centre
PRINCIPAL INVESTIGATOR

Enrollment

500 participants (actual enrollment reported by the registry).

Study Design

Study Type: observational
Observational Model: COHORT
Time Perspective: PROSPECTIVE
Sponsor Type: OTHER
Responsible Party: SPONSOR

Study Record Dates

First Submitted

May 20, 2007

First Posted

May 22, 2007

Study Start

March 2003

Actual (reported)

Primary Completion

A Prospective Cohort of Children With HIV Infection

Brief Summary

Registry Overview

Trial Relationships

Study Timeline

Study Start

First Submitted

First Posted

Primary Completion

Study Completion

Conditions

Keywords

Outcome Measures

Primary Outcomes (1)

Study Arms (1)

Long-term pediatric cohort

Interventions

Registry intervention entries

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (3)

Related Publications (3)

Related Links

Biospecimen

MeSH Terms

Conditions

Interventions

Condition Hierarchy (Ancestors)

Study Officials

Enrollment

Study Design

Study Record Dates

You may not qualify if:

Intervention Hierarchy (Ancestors)

Source record

Locations

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

Study Start

First Submitted

First Posted

Primary Completion

Study Completion

Conditions

Keywords

Outcome Measures

Primary Outcomes (1)

Study Arms (1)

Long-term pediatric cohort

Interventions

Registry intervention entries

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (3)

Related Publications (3)

Related Links

Biospecimen

MeSH Terms

Conditions

Interventions

Condition Hierarchy (Ancestors)

Study Officials

Enrollment

Study Design

Study Record Dates

You may not qualify if:

Intervention Hierarchy (Ancestors)

Source record

Locations